Biological evidence from an experimental AD mouse model has explained that IL-2 triggers the activation of Tregs and astrocytes in APP/PS1 mice and increases the recruitment of astrocytes around amyloid plaques, reducing Aβ and slowing the development of AD (Alves et al., 2016). Here, APP is linked to Alzheimer disease.